ID-5184 Wonca Abstracts supplement A-K 13-10-23 - Flipbook - Page 147
WONCA 2023 Supplement 1: WONCA 2023 abstracts (A–K)
A
B
C
D
iSISTAQUIT: Culturally specific training for healthcare
professionals to support pregnant Aboriginal and Torres
Strait Islander women quit smoking
Dr Nicole Ryan1, Dr Marilyn Clarke1, Sharni Carberry1, Prof Gillian Gould
1
E
F
G
H
I
J
K
Southern Cross University
Around 44% of Aboriginal and/or Torres Strait Islander women smoke during pregnancy compared
to 12% of their general population counterparts. Evidence-based quit smoking advice received from
healthcare professionals (HCPs) can increase smoking cessation rates. However, HCPs lack culturally
appropriate smoking cessation training, which is a major barrier to the provision of smoking cessation
care for this population. There are several cultural aspects related to smoking that may be important
for HCPs to understand when helping Aboriginal and Torres Strait Islander women quit. The aim of
the iSISTAQUIT program is to provide HCPs with culturally specific smoking cessation training. The
online iSISTAQUIT training comprises 14 e-learning modules that take around four hours to complete.
This proposed skill building session will be a condensed version of the online training designed for
face-to-face delivery and for small-group workshopping. The primary goal of this skill-building session
will be to encourage participants to further engage with the culturally specific online training which
was an RACGP Accredited CPD (Cat. 1) Activity for the 2020–22 triennium. HCPs will have increased
knowledge, skills and confidence to provide effective smoking cessation care of pregnant Aboriginal
and/or Torres Strait Islander women. From the skill-building session it is anticipated that participants
will be able to: (1) understand the psychosocial and cultural context of smoking among pregnant
Aboriginal and Torres Strait Islander women; (2) apply culturally safe smoking cessation practices
that support Aboriginal and Torres Strait Islander people; (3) make a quit plan; and (4) conduct a risk/
benefit assessment on the safe use of NRT in pregnancy.
145